A new study led by Dr. Frank Sciurba, published in The New England Journal of Medicine, reveals that mepolizumab can significantly reduce exacerbations in COPD patients with eosinophilic inflammation—affecting up to 40% of those with the disease.
New Study by Dr. Frank Sciurba et al. Shows Promising Results for COPD Treatment
